FORM PTO-1449  TARROTANTION DISCLOSURE CITATION					Atty Docket Serial No. 10/791,862  Applicant Karl F. POPP				
HON 3 "	NFOR	FORM PTO-1449 ATION DISCLOSURE		Filing Date Group Art Unit March 4, 2004 1614			Unit		
U.S. PATENT DOCUMENTS									
Examiner Initial		Document Number			Name	Cla	ass	Sub- Class	Filing Date
	AA								
	AB								
	AC					<u> </u>			
	AD								
	AE			J					
	AF								
	AG								
	AH								
	AI								
	AJ								
	AK					<u>.l</u>			
			FOREIGN P	ATENT DO	CUMENTS				
		Document						Sub- Class	Trans- lation
		Number	Date		Country	1 61	ass	Class	1401011
	AL			<del> </del>		<del>-  </del>			
	AM		<u> </u>						
·	AN			<del> </del>					
	AO								
	AP								
	AR								
		OTHER (Including							
R		Pelle, M.T	. et al.,	''Rosace	a: II. Therapy' (Oct 2004).	'' <u>J</u>	Am A	cad Der	matol,
	AS	vol. 51, n	o. 4, pp.	477-312					
	]								
	AT								
	ΑU								
Examiner	L	. Cham	avan	Jele	Date Considere	ed	6	22/	9
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP * 609.  Draw line through citation if not in conformance and not considered.  Include copy of this form with next communication to Applicant.									

OIPE				****	Atty Docket		Ser	ial No.	
Ý	3	24948-X 10/791,862			1,862				
OCT 0 1 2004	<b>&amp;</b> )	FORM PTO-1449			Applicant Karl F. POPP				
- A 2	NFORM.	Filing Date Group Art Unit March 4, 2004 1614							
U.S. PATENT DOCUMENTS									
Examiner Inițial		Document Number	Publish Date		Name	Cla	ıss	Sub- Class	Filing Date
	AA	2004/0156873	Aug. 12, 2004	-	Gupta				Feb. 10, 2003
	AB	2004/0151671	Aug. 5, 2004	Ab:	ram, et al.				Jan. 23, 2004
	AC								
	AD								
	AE								
	AF								
	AG			-					
	AH								
	AI								
	AJ								
	AK					<u>]</u>			
			FOREIGN PA	ATENT DO	CUMENTS				
		Document Number	Date		Country	Cla	ass	Sub- Class	Trans- lation
	AL								
	АМ								
	AN								
	AO								
	AP					<u> </u>			
	(	OTHER (Including	Author, Ti	tle, Dat	te, Pertinent Pa	ges,	et	c.)	
	AR								
	AS								
	AT								
Examiner									
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.  Draw line through citation if not in conformance and not considered.  Include copy of this form with next communication to Applicant.									

OIPE E					Atty. Docket Serial No. 24948X 10/791,862			1,862	
<i>w</i> )	1 1 2 2	መ 발 FORM PTO-1449			Applicant POPP				
794	NFORM	Filing Date Group Art Unit March 4, 2004 1614							
	* TRAUS		U.S. PAT	ENT DOC			<u> </u>		
Examiner								Sub-	Filing
Initial		Number	Date		Name	Cla	155	Class	Date
	AA								
	AB AC					<del>-  </del>			
	AD			-					
	AE			<del></del>		<del>                                     </del>			
	AF								
	AG		_						
	AH								
	ΑI								
		1	FOREIGN P	ATENT DO	CUMENTS				
		Document Number	Date	Country		cı	ass	Sub- Class	Trans- lation
	AJ								
	AK								
	AL								
	AM			ļ					
	AN								
	AO		( 	<del>}</del>				ļ	
ļ	AP			-					
	AQ			<u> </u>		<u></u>		1	
<u> </u>	1	T T T T T T T T T T T T T T T T T T T			te, Pertinent P				
	AR	Laude et a Surg., 199	l., "Perio 9, 18(3),	ral Derm 206-209.	natitis in Chil	dren"	, <u>S</u> e	emin. C	utan. Med.
	AS	Hogan et al., "Perioral dermatitis: an uncommon condition?", CMAJ, 1986, 134, 1025-1028.							
	АТ	Dahl et al., "Temperature regulates bacterial protein production: Possible role in rosacea", J. Am. Acad. Dermatol., 2004, 50(2), 266-272.							
	AU	Wilkin et al., "Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea", J. Am. Acad. Dermatol., 2002, 46(4), 584-587.							
A.	AV	Wilkin, "Rosacea: Pathophysiology and Treatment", Arch. Dermatol., 1994, 130, 359-362.							
Examiner									9
				/ 0				1	

FORMATION DISCLOSURE CITATION

FORM PTO-1449

Atty. Docket 24948X

Serial No. 10/791,862

Applicant

POPP

Filing Date March 4, 2004

Group Art Unit 1614

* TRAUES				March 4, 200	4	16	14
			U.S. PAT	ENT DOCUMENTS			
Examiner Inipial		Document Number	Issue Date	Name	Class	Sub- Class	Filing Date
<u> </u>	AA	3,867,522	02/18/75	Kligman			10/11/7
	AB	3,952,099	04/20/76	Smith			01/17/7
	AC	3,969,516	07/13/76	Stoughton			07/07/7
	AD	4,364,940	12/21/82	Neiss et al.			02/23/8
	AE	4,387,107	06/07/83	Klein et al.			12/16/8
	AF	4,443,442	04/17/84	Skillern			12/21/7
	AG	4,497,794	02/05/85	Klein et al.			01/03/8
	AH	4,505,896	03/19/85	Bernstein			11/24/8
	AI	4,671,956	06/09/87	Bouillon et al.			10/14/8
	AJ	4,692,329	09/08/87	Klein et al.			07/03/8
	AK	4,731,362	03/15/88	Hamashima et al.			07/23/8
	AL	4,803,228	02/07/89	Jacquet et al.			09/29/8
	AM	4,906,617	03/06/90	Jacquet et al.			09/29/8
	AN	5,260,292	11/09/93	Robinson et al.			05/12/9
	AO	5,409,917	04/25/95	Robinson et al.			09/24/9
	AP	5,446,028	08/29/95	Klein et al.			04/08/9
	AQ	5,466,446	11/14/95	Stiefel et al.			02/16/9
	AR	5,648,389	07/15/97	Gans et al.			10/27/9
	AS	5,654,013	08/05/97	Taylor et al.			03/13/9
	АТ	5,707,635	01/13/98	Deckner et al.			05/25/9
	AU	5,733,886	03/31/98	Baroody et al.			04/28/9
	AV	5,756,119	05/26/98	Deckner et al.	<del></del>		06/05/9
	AW	5,767,098	06/16/98	Klein et al.			03/31/9
	AX	5,849,776	12/15/98	Czernielewski et al.	-		03/25/9
	AY	5,939,083	08/17/99	Allec et al.			06/09/9
	AZ	5,948,416	09/07/99	Wagner et al.	<u> </u>		05/08/9
	AAA	5,952,372	09/14/99	McDaniel			09/14/9
	AAB	5,972,993	10/26/99	Ptchelintsev			10/26/9
	AAC	5,998,395	12/07/99	Kligman			12/07/9
	AAD	6,013,637	01/11/00	Klein et al.			06/12/9
	AAE	6,071,541	06/06/00	Murad			06/11/9
	AAF	6,074,653	06/13/00	Wilcox et al.			07/30/9
	AAG	6,117,843	09/12/00	Baroody et al.		-	05/13/9
xaminer	1 -	Channa		Date Considered	6	122	Par

				<del> </del>	<del></del>	<del></del>		<u>P</u>	age 2 of 3	
			Atty. Docket Serial No. 24948X 10/791,862							
		Applicant POPP								
		ŀ	Filing Date Group Art Unit			Unit				
	NPORM	ATION DISCLOSURE	CITATION		March 4, 2004		<u> </u>		14	
	U.S. PATENT DOCUMENTS									
Examiner Initial	:	Document Number	Issue Date	Name			ss	Sub- Class	Filing Date	
#0	ва	6,133,310	10/17/00		Parks				08/26/99	
	BB	6,136,806	10/24/00		Hittel				11/20/98	
	BC	6,174,534	01/16/01	Ricl	nard et al.				02/03/99	
	BD	6,241,993	06/05/01		ton et al.				06/01/98	
	BE	6,331,307	12/18/01	Sebillo	otte-Arnaud et al.		l		07/14/00	
	BF	6,331,551	12/18/01		Subbiah		一		11/13/00	
	BG	6,352,724	03/05/02	Tav	lor et al.				03/11/96	
	ВН	6,387,383	05/14/02		ow et al.				08/03/00	
	BI	6,482,839	11/19/02		nornfeldt				09/02/98	
	ВJ	6,573,301	06/03/03	Glas	sman et al.	-			04/23/02	
	BK	2003/0049212	03/13/03		nson et al.				04/25/02	
	BL	2003/0064084	04/03/03		gwat et al.				09/24/01	
	ВМ	2003/0077301	04/24/03		oach et al.				06/21/02	
	BN	6,440,994	08/27/02	Sai	nders, Jr.				08/27/02	
	ВО	6,495,158	12/17/02	Bus	eman et al.				01/19/01	
	BP	6,517,847	02/11/03	D	ow et al.				03/08/02	
	BQ	6,586,472	07/01/03	P	erricone				09/14/01	
	BR	6,599,512	07/29/03		Burnier				10/03/97	
V	BS	2003/0228340	12/11/03		Gans				04/04/03	
			FOREIGN P	ATENT DO	CUMENTS					
Jb.		Document Number	Date		Country	Cla	88	Sub- Class	Trans- lation	
	вт	WO 93/15726	08/19/93		PCT				Yes	
	BU	WO 93/20796	10/28/93		PCT				Yes	
		OTHER (Including	Author, Ti	tle, Dat	e, Pertinent Pag	geв,	eto	2.)		
	BV	Langer et Pharmacolo			Acne Vulgaris",	AFP	Cl	inical		
	Gloor et al., "Topical treatment of acne vulgaris with erythromycin and benzoylperoxide" (Abstract), Z. Hautkr., 1992, 57(12), 867-878.									
	вх	Tucker et al., "Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris" (Abstract), Br. J. Dermatol., 1984, 110(4), 487-492.								
	BY Gerny, "Experiences in dermatologic practice with combined external treatment of acne with benzoyl peroxide and erythromycin" (Abstract), Z. Hautkr., 1984, 59(13), 888-893.									
Examiner	Examiner Channaragal Date Considered of 2767									
				/I-/						

				Atty. Docket 24948X	Serial No. 10/791,862				
				Applicant					
					POPP				
		FORM	PTO-1449		TOPP				
· <u>1</u>	NFORM	ATION D	ISCLOSURE CITATION	Filing Date March 4, 2004	Group Art Unit				
1	(	OTHER (I	ncluding Author, Title, I		etc.)				
R	CA	M t r 2	arsden, "Evidence that me reatment with benzoyl per esponse of acne" (Abstrac 5-28.	thod of use, dose and oxide and tetracyclingt), J. R. Soc. Med.,	duration of e determined 1985, 78 Suppl. 10,				
	СВ	t t	orris et al., "A comparis etracycline, benzoyl-perc reatment of acne" (Abstra 1-33.	oxide gel and oral tet act), <u>Clin. Exp. Derma</u>	racycline in the tol., 1991, 16(1),				
	Lookingbill et al., "Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: Combined results of two double-blind investigations", J. Am. Acad. Dermatol., 1997, 37(4), 590-595.								
	CD	B	eyden et al., "The Combin enzoyl Peroxide 5% versus lindamycin Alone in the F . Clin. Dermatol., 2001,	s 3 Different Formulat Reduction of <i>Propionit</i> 2(4), 263-266.	ions of Topical      pacterium acnes", <u>Am.</u>				
	CE	L	eyden, "Current issues in f acne", J. Eur. Acad. De 1-55.	antimicrobial therap	y for the treatment 001, 15 (Suppl. 3),				
	CF	t	evy, "Dermatopharmacology he Topical Treatment of A	of a New Combination Acne", <u>CUTIS</u> , 2001, 67	Gel Formulation for 7, 8-12.				
/	CG	В	enzaClin <sup>™</sup> Topical Gel Pro	escribing Information	, Feb. 2002.				
	Tuleya et al., "Research Highlights of Acne and Rosacea Treatments: The latest research from recent AAD meetings and more", Skin & Aging, Aug. 2003, 70-72.								
Examiner	L	· ()	hannavajele	Date Considered	6/22/0				
			10						
			V						